Compare WRLD & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | LYEL |
|---|---|---|
| Founded | 1962 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.2M | 745.5M |
| IPO Year | 1991 | 2021 |
| Metric | WRLD | LYEL |
|---|---|---|
| Price | $140.50 | $24.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 108.1K | ★ 138.8K |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.75 | N/A |
| Revenue | ★ $570,762,378.00 | $41,000.00 |
| Revenue This Year | $0.89 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $12.92 | ★ N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $104.99 | $7.65 |
| 52 Week High | $185.48 | $45.00 |
| Indicator | WRLD | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 39.40 |
| Support Level | $137.27 | $22.38 |
| Resistance Level | $146.20 | $25.12 |
| Average True Range (ATR) | 6.35 | 2.44 |
| MACD | -0.72 | -1.11 |
| Stochastic Oscillator | 26.26 | 10.05 |
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.